|
MediciNova's MN-166 Program Recognized as One of Windhover's Top 10 …
MarketWatch (press release) Ibudilast is marketed in Japan and South Korea for the treatment of asthma and cerebrovascular disorders for which MediciNova discovered its potential as a … |
View full post on asthma – Google News